Loading stock data…
$4.43-0.10 (-2.21%)
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
RxSight, Inc. in the Healthcare sector is trading at $4.43 with a market capitalization of $265M. Wall Street consensus targets $7.57 (8 analysts), implying a +70.9% move over the next 12 months. The stock is currently near its 52-week low of $4.40, remaining 33.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $33.74M↑ | $30.89M↓ | $32.61M↑ | $30.34M↓ | $33.64M |
| Gross Profit | $25.89M↑ | $23.50M↓ | $25.26M↑ | $24.23M↓ | $25.19M |
| Operating Income | -$13.77M↑ | -$17.83M↓ | -$11.34M↑ | -$12.18M↑ | -$14.00M |
| Net Income | -$12.10M↑ | -$15.88M↓ | -$9.15M↑ | -$9.82M↑ | -$11.79M |
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that ena...